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Abstract: Angiogenesis has a significant part in the pathogenesis of hematological malignancies, such as leukemia and 
myelodysplastic syndromes (MDS). We evaluated the relationship between morphometric, morphological and clinical 
features of MDS. Blood vessels of 31 newly diagnosed MDS bone marrow biopsies were immunohistochemically 
analyzed using CD34 and compared with 8 controls and 13 chronic myelomonocytic leukemias (CMML). MDS were 
categorized into three risk groups: low-, intermediate- and high-risk MDS. 
Microvascular density (MVD) and major and minor axis length were analyzed using digital image analysis. Overall, 
MDS had significantly higher MVD and lower minor axis values than the control group and CMML. High-risk MDS had 
significantly higher MVD compared to the controls, while all MDS risk groups had lower minor axis values than the 
control group.  Increased minor and major axis values were prognostic predictors of shorter overall survival in all MDS 
risk groups and CMML patients. In conclusion, angiogenesis presents one of the essential factors in MDS pathogenesis 
and progression characterized by descriptive marrow microvascular network transformation. The size-related features 
are powerful indicators of survival in MDS patients. 
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Myelodysplastic syndromes (MDS) are a group of 
clonal hematopoietic stem cell diseases characterized by 
cytopenia, dysplasia in one or more of the major myeloid 
lineages, ineffective hematopoiesis, recurrent genetic 
abnormalities and increased risk of developing acute 
myeloid leukemia (AML).1-4 
MDS subtypes are based on morphological features, the 
percentage of blasts in the bone marrow (BM) and 
peripheral blood, the type and degree of dysplasia, and 
the percentage of ring sideroblasts, according to the 
WHO classification of MDS.4 
Most subtypes are characterized by progressive BM 
failure or progression to AML that is the natural course 
in many cases of MDS, but the biological course of some 
subtypes is prolonged and indolent, with a very low 
incidence of evolution to AML.5, 6 
The subtypes of MDS can be generally categorized into 
three risk groups on the basis of survival time and 
incidence of evolution to AML. The importance of 
cytogenetic features as prognostic indicators in MDS 
was codified by The Revised International Prognostic 
Scoring System (IPSS-R score) that predicts survival 
and risk of evolution to AML.7 
The formation of new blood vessels from pre-existing 
vessels is essential to growth, invasion and metastasis by 
solid tumors and occurs in other diseases, including 
autoimmune disease and diabetes mellitus.8-11 
Angiogenesis has recently been reported in 
hematological malignancies, such as leukemia and 
myelodysplastic syndromes.12-18 The issue of 
angiogenesis in MDS has been validated in several 
studies providing evidence of increased bone marrow 
MVD in MDS.13, 17, 18 Impaired homeostasis of inducers 
and inhibitors of angiogenesis released from tumor cells 
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and recruited host cells may occur, usually in response 
to alterations in the microenvironment (e.g. hypoxia).19 
Moreover, intracellular levels of vascular endothelial 
growth factor (VEGF), a potent angiogenic molecule, 
have prognostic significance in AML20 and chronic 
lymphocytic leukemia.21  
In some studies, the highest MVD counts were observed 
in the MDS subgroups, chronic myelomonocytic 
leukemia (CMML) and refractory anemia with excess of 
blasts in transformation (RAEB-t),20 while in other 
studies they were found in refractory anemia (RA) and 
RAEB,23 and one study failed to show significant 
differences between subtypes.16 Vascular variables were 
associated with progression-free survival, and overall 
survival.23  
Using von Willebrand factor or CD3116, 22, 23 as markers 
for vascular endothelial cells (EC) to estimate 
vascularization can be insufficient since they are also 
expressed in megakaryocytes and platelets.20, 24 
In the present study, we used the CD34 marker for EC 
to investigate the relationship between MVD and patient 
survival, common clinicopathological factors, and the 
IPSS–R. 
The study results might ascertain the evolution of the 
disease and assess the clinical significance of 
angiogenesis in MDS patients. 
 
 
PATIENTS AND METHODS 
Patients 
Paraffin-embedded BM biopsies obtained at diagnosis 
from 31 consecutive patients with MDS between 2011 
to 2016 were studied. A control group of eight subjects 
with no evidence of BM disease were evaluated: four 
cases as part of staging procedure for Hodgkin’s disease, 
two cases of non-Hodgkin’s lymphomas, one case of 
solid tumor, and one case of osteoporosis-related 
pathological fracture. 
The study was approved by the University Hospital 
Merkur Ethical committee, and informed consent was 
obtained from patients. 
MDS diagnosis was established by morphologists, the 
classification of MDS was confirmed by hematologists, 
according to the WHO classification.4  
MDS patients were categorized into three risk groups.6 
The low-risk group (MDS-LR) includes MDS with 
single lineage dysplasia, MDS with ring sideroblasts and 
single lineage dysplasia, and MDS with isolated del 
(5q). 
The intermediate-risk group (MDS-IR) contains MDS 
with multilineage dysplasia and MDS with ring 
sideroblasts and multilineage dysplasia.  
The high-risk group (MDS-HR) consists of MDS with 
excess of blast 1 and 2.  
The category of MDS, unclassifiable, was not evaluated 
in this study.  
Although chronic myelomonocytic leukemia (CMML) 
was excluded from MDS, these entities share similar 
features, and 13 cases of CMML were included in our 
study to examine the possible differences between 
CMML and MDS subtypes. 
In the MDS group there were 18 males and 13 females 
with a median age of 74 years (range, 42-90). The 
frequencies of MDS risk groups were: MDS-LR six 
cases, MDS-IR nine cases and MDS-HR 16 cases. In the 
CMML group there were 12 males and one female with 
a median age of 70 years (range, 44-90). In the control 
group there were five males and three females with a 
median age of 68 years (range, 46-8). The results of 
laboratory tests are shown in Table 1 and 2. 
Cytogenetic abnormalities were scored according to the 
CCSS for MDS (Table 3). 
 
 
Table 1. Laboratory and clinical features of myelodysplastic syndrome, myelodysplastic syndrome risk groups and chronic myelomonocytic 
leukemia (median, range). 
Legend: CCSS karyotype and IPSS-R score variables were analyzed in MDS-LR (N=6), MDS-IR (N=8), MDS-HR (N=14), CMML (N=8). 
MDS - myelodysplastic syndrome, LR - low risk, IR - intermediate risk, HR - high risk, CMML - chronic myelomonocytic leukemia, CCSS karyotype 
- Comprehensive Cytogenetic Scoring System karyotype,25 IPSS-R score -The Revised International Prognostic Scoring System,7 ECOG - Eastern 


















































125.5 (73-277) 88 (80-149) 78.5 (50-118) 87 (52 - 149) 132 (90-362) - 91.5 (58-153.5) 
Blasts      
(%) 
1 (1-1) 2 (1-3) 8 (5.5-12) 5 (1 - 8) 3 (1-6) - 4 (1-7.5) 
CCSS 
karyotype 
1.5 (1-3) 1.5 (1-2.5) 1.5 (1-3) 1.5 (1 - 3) 1 (1-2) - 1 (1-3) 
IPSS-R 
score 
3 (2.5-3) 2.5 (2-4.25) 4.75 (3.5-8) 3.5 (2.75 - 5.25) 2.75 (1.75-3.5) - 3.5 (2.5-5) 
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Table 2. The Revised International Prognostic Scoring System 
values distribution of hemoglobin, absolute neutrophil count and 
platelets in myelodysplastic syndrome risk groups and chronic 
myelomonocytic leukemia patients± 
± IPSS-R score – The Revised International Prognostic Scoring System 
values for myelodysplastic syndromes.7 
Legend: MDS - myelodysplastic syndrome, LR - low risk, IR - 
intermediate risk, HR - high risk, CMML - chronic myelomonocytic 
leukemia, HB - hemoglobin concentration, NEU -  absolute neutrophil 
count, PTL -  platelets. 
*Hemoglobin concentration ≥100 g/L; Absolute neutrophil count 
≥8x109/L, Platelets ≥100x109/L 
**Hemoglobin concentration <100 g/L; Platelets 50 to <100x109/L 
***Hemoglobin concentration <50 g/L; Absolute neutrophil count 
<8x109/L, Platelets <50 x109/L 
 
 
Transfusion was administered in 3/6 (50%) cases of 
MDS-LR, 8/9 (88.8%) cases of MDS-IR, 8/16 (50%) 
cases of MDS-HR, and 7/13 (53.8%) cases of CMML. 
Chemotherapy was administered in 1/9 (11.1%) cases of 
MDS-IR, 10/16 (62.5%) cases of MDS-HR, and 4/13 
(30.7%) cases of CMML. Patients were treated with 
azacidine in all cases except one where idarubicin was 
administered.  
A median follow-up period for patients without disease 
progression or lethal outcome was 48.3 (range 31.80-
91.46) months. A median follow-up period of patients’ 
 
 
Table 3. Cytogenetic abnormalities in myelodysplastic syndrome 
risk groups and chronic myelomonocytic leukemia patients 
Legendy: CCSS karyotype - Comprehensive Cytogenetic Scoring 
System (CCSS) karyotype25, MDS - myelodysplastic syndrome, LR - 
low risk, IR - intermediate risk, HR - high risk, CMML - chronic 
myelomonocytic leukemia 
disease progression was 8.01 (range 1.43-30.03) months 
in 14 (45.1%) MDS patients, and six (46%) CMML 
patients. Overall, 5/14 (35.7%) MDS cases, and 4/6 
(66.6%) CMML cases progressed to AML. The rest of 
MDS cases progressed into higher risk MDS (9/14 
cases; 64.2%), while 2/6 (33.3%) cases of CMML 
progressed to myelofibrosis. 
A median follow-up period with lethal outcome was 
10.85 (range 1.00-36.56) months, 11/44 (25%) patients 





FFPE decalcified (Osteosoft, Merk) BM biopsies and 
smears of peripheral blood and BM aspirate smears were 
processed routinely, and evaluated at the time of the 
diagnosis.  
An analysis of FFPE BM biopsies, peripheral blood and 
BM aspirate smears was performed to establish the 
morphologic classification of MDS and CMML 
according to the WHO classification.4 
Recurrent MDS cytogenetic abnormalities were 
identified by conventional karyotyping and interphase 
FISH.  
Sequentially sectioned 4-μm-thick slides were used for 
performing immunohistochemical staining performed 
by an automated immunostainer (Dako Autostainer 
Plus, Dako-Cytomation, Glostrup, Denmark) using 
LSAB HRP and HRP+ kits according to the 
manufacturer's instructions.  
CD34 antibody was used for establishing EC (mouse 
monoclonal, Dako; QBEnd 10, RTU) according to the 
manufacturer’s instructions. A CD34 expression 
positive control was the appendix. For the negative 
control, adjacent sections were stained in the absence of 
a primary antibody. 
 
 
Analysis of bone marrow microvasculature 
Immunohistochemically stained slides were analyzed 
using an Olympus 71 digital camera and an Olympus 
BX51 microscope. Complete BM section was scanned 
at x100 magnification to assess the area showing the 
most intense vascularization, the “hot spot”.26 
After determining the “hot spots” at x100 magnification, 
the same areas were consecutively analyzed at x200 
magnification until the highest number of microvessels 
was included within the x200 field. The “hot spots” at 
x200 magnification within intertrabecular cellular area 
were eligible for analysis avoiding connective and fat 
tissue as well as trabeculae.  
 “Hot spots” were saved as uncompressed 24-bit RGB 
TIFF files, analyzed and measured in the software 
program AnalySIS (Olympus Soft Imaging System 
GmbH, Munster, Germany) calibrated with the adequate 
micrometer scale.  
The consensus of morphological criteria for 
microvessels was followed.26, 27 Any brown-stained EC 
 HB NEU PTL 
MDS-LR 
    Normal* 4 6 3 
    Decreased – milder degree** 2 0 2 
    Decreased – higher degree*** 1 0 1 
MDS-IR    
    Normal* 6 6 4 
    Decreased – milder degree** 2 0 3 
    Decreased – higher degree*** 1 3 3 
MDS-HR 
    Normal* 11 10 6 
    Decreased – milder degree** 4 0 6 
    Decreased – higher degree*** 1 6 4 
CMML 
    Normal* 10 13 7 
    Decreased – milder degree** 2 0 3 








CCSS karyotype     
    Very good 0 0 0 0 
    Good  3 4 7 5 
    Intermediate 1 2 1 2 
    Poor  2 1 4 1 
    Very poor 0 1 3 0 
    NA 0 1 2 5 
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or cluster, with or without a lumen, which was clearly 
separated from adjacent microvessels and other BM 
cells was considered as a single, countable microvessel. 
Blood cells or fibrin without any detectable EC were not 
sufficient for defining a microvessel. Vessels with 
muscular walls were also not counted; however, there 
was no restriction regarding the size of the countable 
vessels.28 
In addition to EC, the myeloblast is also CD34 positive 
but can be distinguished from EC by characteristic 
morphology and granular intracytoplasmic and Golgi-
type positivity with alterative membrane positivity. EC 
show predominantly membranous positivity. 
Microvasculature morphometric parameters estimated 
in this study were major axis length (the distance 
between the two points along the vessel periphery that 
are furthest apart), minor axis length (the longest axis 
perpendicular to the major axis formed by two points 
along the vessel periphery), and the total count of 
microvessels per optical field (MVD).28  





Descriptive statistics are presented through frequencies 
and percentages for nominal variables, and through 
medians and interquartile ranges for continuous 
variables. Deviations from normal distributions for each 
group were assessed using Kolmogorov-Smirnov tests 
and visual inspection of result distributions. Almost all 
variables deviated significantly from the normal 
distribution for at least one group, and visual inspection 
did not suggest normality. Because of deviations from 
normality and ordinal nature of some variables, non-
parametric Kruskal-Wallis H tests were used to compare 
groups. Group differences by nominal variables were 
assessed using chi-square tests of independence with 
exact p-values to avoid difficulties due to cells with 
expected frequencies lower than five. Survival analyses 
were carried out to determine differences in survival 
functions for different variables. Statistical analyses 
were performed using SPSS software (SPSS, Chicago, 
IL, USA). The alpha value was set to 5%. 
RESULTS 
Morphometric morphological features were measured 
for MDS, MDS risk groups CMML, the control group 
(Table 4, Figure 1). 
 
 
Kruskal-Wallis H tests 
Two sets of intergroup analyses were performed. CCSS 
karyotype, hemoglobin, platelets and IPSS-R score did 
not differ significantly across groups; one with separate 
MDS low-risk, intermediate-risk and high-risk groups, 
and one with grouped MDS patients.  
Separate group differences are examined first (Table 5, 
Separate MDS). The test found statistically significant 
omnibus differences in MVD between groups with 
relatively strong effect size (P=.003, ε2=.321). 
Bonferroni-corrected post hoc test found that high-risk 
MDS patients had higher MDS than the control group 
(P=.003). Minor axis length also showed strongly 
pronounced significant differences across groups 
(P<.001, ε2=.413), with the control groups having 
greater minor axis length than low-risk (P=.016), 
intermediate-risk (P=.006) and high-risk MSD patients 
(P=.003). Major axis length was significantly different 
across groups, a relatively strong effect (P=.007, 
ε2=.278), with CMML patients having greater major 
axis length than the control group (P=.008). While 
neutrophils analysis showed significant differences in 
the omnibus test (P=.014, ε2=.247), post hoc tests found 
no significant differences between groups. It is 
concluded that there are no significant neutrophil 
differences across groups. The strongest effect was 
found in the analysis of the number of blasts (P<.001, 
ε2=.623), with high-risk MDS patients having 
significantly more blasts than low-risk (P<.001) and 
intermediate-risk  MDS   patients  (P=.001)  as  well  as 
CMML patients (P=.006). The IPSS-R score differed 
relatively strongly and significantly across groups 
(P=.006, ε2=.356), with high-risk MSD patients having 
higher scores than CMML patients (P=.045). 
 
 
Table 4. Morphometric morphological features of myelodysplastic syndrome, myelodysplastic syndrome risk groups and chronic 
myelomonocytic leukemia (median, range) 
Legend: MDS - myelodysplastic syndrome, LR - low risk, IR - intermediate risk, HR - high risk, CMML – chronic myelomonocytic leukemia,   
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Figure 1. Immunohistochemical staining CD34 of bone marrow microvasculature (magnification x100);  A.  Control group  (PHD#2492-16),  




ECOG results were overall significantly different with a 
relatively strongly pronounced effect (P=.021, ε2=.226), 
and with high-risk MSD patients having higher results 
than CMML patients (P=.043). CCSS karyotype, 
hemoglobin, platelets and IPSS-R score did not differ 
significantly across groups.  
Analyses of grouped MDS patients produced the 
following results (Table 5, Grouped MDS). MVD 
differed across groups relatively strongly and 
significantly (P=.006, ε2=.356). Post hoc test found 
significantly higher results for MDS patients than the 
control group (P=.008). Minor axis length differed 
strongly and significantly across groups as well (P<.001, 
ε2=.402), with MDS patients achieving lower results 
than CMML patients (P=.008) and the control group 
(P<.001). Relatively strong significant differences were 
found in major axis length (P=.004, ε2=.222), with 
CMML patients having greater lengths than the control 
group (P=.002). The rest of the analyses did not include 
a control group, leaving only MDS and CMML patients, 
so no post hoc tests were performed. CMML patients 
had significantly more neutrophils than MDS patients, 
with a relatively strongly pronounced effect size 
(P=.004, ε2=.195). CMML patients also achieved a 
significantly higher performance status than MDL 
patients, with a moderately pronounced effect site 
(P=.044, ε2=.094). CCSS karyotype, hemoglobin, 
platelets, blasts and IPSS-R score did not differ 
significantly across groups. 
 
 
Chi-square tests of independence 
Chi-square tests of independence found statistically 
significant differences between groups based on type of 
therapy applied, with a strongly pronounced effect size 
(χ2 (6)=18.54, P=.004, V=.649) (Table 6). To examine 
which specific cells differed from their expected 
frequencies significantly, adjusted standardized 
residuals were calculated. Intermediate-risk MDS 
patients received transfusions more frequently than 
expected by chance (z=2.52, p=.012). High-risk MDS 
patients received chemotherapy significantly more 
frequently (z=3.01, p=.003). Disease outcome, 
transfusion and progression of disease did not differ 
significantly among groups. 
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Table 5. Kruskal-Wallis H test results and Bonferroni-corrected Dunn post hoc group comparisons of myelodysplastic syndrome, 
myelodysplastic syndrome risk groups, chronic myelomonocytic leukemia and the control group 
Legend: P - significance of Kruskal-Wallis H test, ε2 - epsilon squared effect size, in group difference comparisons the group to the left of the hyphen 
has a significantly higher score 
MDS(lr) - myelodysplastic syndrome-low risk, MDS(ir) - myelodysplastic syndrome-intermediate risk, MDS(hr) - myelodysplastic syndrome-high risk, 
CMML - chronic myelomonocytic leukemia, X0 - control group, MVD - microvascular density, CCSS karyotype - Comprehensive Cytogenetic Scoring 




Kaplan-Meier survival analyses 
Log rank tests were calculated as part of Kaplan-Meier 
survival analysis to find differences in survival functions 
for different variables. MVD, minor axis length and 
major axis length values were categorized based on the 
median value (Table 7). Log rank test found a significant 
difference in survival functions for minor axis lengths 
(χ2 (1)=6.418, P=.011) (Figure 2) and major axis lengths 
(χ2 (1)=8.658, P=.003) (Figure 3). For both variables, 
patients above the median had lower time until death 
than those below the median. Differences between 
survival functions did not differ significantly for 
examined groups (Figure 4), MVD (Figure 5), CCSS 




Table 6. Crosstabs and chi-square tests of differences between myelodysplastic syndrome risk groups and chronic myelomonocytic leukemia 
by outcome, transfusion administration, progression of disease and type of therapy 
Legend: f - frequency, % - percentage of answers within a group, z - adjusted standardized residuals, χ2 - chi-square test result, P - exact statistical 
significance of the chi-square test, V - Cramer's V effect size; MDS - myelodysplastic syndrome, LR - low risk, IR - intermediate risk, HR - high risk, 
CMML - chronic myelomonocytic leukemia 
Separate MDS P ε2 Significant group differences 
MVD .003 .321 MDS(hr) - X0   
Minor axis length <.001 .413 X0 - MDS(lr) X0 - MDS(ir) X0 - MDS(hr) 
Major axis length .007 .278 CMML - X0   
CCSS karyotype .750 .035 -   
Hemoglobin .860 .018 -   
Neutrophils .014 .247 -   
Platelets .273 .091 -   
Blasts <.001 .623 MDS(hr) - (lr) MDS(hr) - (ir) MDS(hr)-CMML 
IPSS-R score .006 .356 MDS(hr)-CMML   
ECOG .021 .226 MDS(hr)-CMML   
Grouped MDS P ε2 Significant group differences 
MVD .011 .177 MDS - X0   
Minor axis length <.001 .402 CMML - MDS X0 - MDS  
Major axis length .004 .222 CMML - X0   
CCSS karyotype .319 .028 -   
Hemoglobin .455 .013 -   
Neutrophils .004 .195 CMML - MDS   
Platelets .114 .058 -   
Blasts .215 .036 -   
IPSS-R score .093 .081 -   
ECOG .044 .094 MDS - CMML   
  MDS-LR MDS-IR MDS-HR CMML Total χ2 (df),  P, V 
Survived f (%) 4 (66.67) 6 (66.67) 13 (81.25) 10 (76.92) 33 (75.00) χ
2 (3) = 0.915 
P = .829 
V = .144 Died f (%) 2 (33.33) 3 (33.33) 3 (18.75) 3 (23.08) 11 (25.00) 
Transfusion f (%) 3 (50.00) 8 (88.89) 8 (50.00) 7 (53.85) 26 (59.09) χ
2 (3) = 4.206 
P = .259 
V = .309 No transfusion f (%) 3 (50.00) 1 (11.11) 8 (50.00) 6 (46.15) 18 (40.91) 
Progression f (%) 3 (50.00) 4 (44.44) 7 (43.75) 6 (46.15) 20 (45.45) χ
2 (3) = 0.075 
P = 1 
V = .041 No progression f (%) 3 (50.00) 5 (55.56) 9 (56.25) 7 (53.85) 24 (54.55) 
Transfusion therapy 
f (%) 3(50.00) 7(77.78) 1 (6.25) 7(53.85) 18(40.91) 
χ2 (6) = 18.54  
P = .004 
V = .649 
z 0.49 2.52 -3.53 1.13 - 
P .626 .012 <.001 .258 - 
       
Chemo-therapy 
f (%) 0 (0.00) 1 (11.11) 10 (62.50) 4 (30.77) 15 (34.09) 
z -1.90 -1.63 3.01 -0.30 - 
P .058 .103 .003 .763 - 
       
No therapy 
f (%) 3 (50.00) 1 (11.11) 5 (31.25) 2 (15.38) 11 (25.00) 
z 1.52 -1.08 0.72 -0.95 - 
P .128 .281 .469 .340 - 
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Table 7. Log rank test estimating overall survival in 
myelodysplastic syndrome and chronic myelomonocytic leukemia 
Legend: χ2 - chi-square value of log rank test, df - degrees of freedom, 
P - statistical significance. * median split variables. 
MDS - myelodysplastic syndrome, CMML -  chronic myelomonocytic 
leukemia, MVD - microvascular density, CCSS karyotype - 
Comprehensive Cytogenetic Scoring System karyotype, IPSS-R score 





Although it is established that angiogenesis is implicated 
in the progression of hematological malignancies and in 
particular in MDS, the controversial results of a limited 
number of studies require further investigation of 
microvasculature in MDS subtypes and risk-stratified 
subgroups.  
Three studies showed higher MVD in MDS than in 




MVD differs between morphological subgroups MVD, 
with higher MVD in CMML and RAEB-t in previous 
studies.20, 22 In contrast, Korkolopoulou P et al. showed 
higher MVD in RA and RAEB. One study found 
significant differences between subgroups.16 Vascular 
variables were associated with progression-free and 
overall survival.23 
Also, increased BM angiogenesis and circulating 
angiogenic cytokines in patients with myeloproliferative 
diseases highlight the application of anti-angiogenic 
therapies as alternative or auxiliary treatments in 
MDS.29-32  
We confirmed previous observations that patients with 
MDS exhibit higher levels of 
MVD in comparison to the control group. We also 
obtained higher levels of the major axis in CMML 
patients in comparison to the control group.16, 20 
We found significantly higher major axis values in 
CMML than in the control group. 
Minor axis values in MDS were significantly lower in 
comparison to CMML and the control group. 
We extended the investigation further by analyzing 
microvasculature according to WHO classification 
MDS subtyping and risk-stratifying groups of MDS.4, 6 
MDS-HR has significantly higher MVD values than the 
control group, confirming the data reported by recent 
studies.20, 22, 23 
Minor axis values in MDS-LR, MDS-IR, MDS-HR 




Figure 2. Survival rates through time in relation to median split minor axis length 
Variable χ2 df P 
MDS groups and CMML 3.542 3 .315 
MVD* 0.113 1 .737 
Minor axis length* 6.418 1 .011 
Major axis length* 8.658 1 .003 
CCSS karyotype 2.107 3 .551 
Progression 1.108 1 .293 
Therapy 0.008 2 .996 
IPSS-R score 3.906 4 .419 
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Figure 4. Survival rates through time in relation to explored groups 
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Figure 5. Survival rates through time in relation to median split MVD 
 
 
Therefore, the lower minor axis values in all three MDS 
risk groups can point at the different angiogenic 
processes which occur in BM. Two basic types of 
angiogenesis, sprouting and intussusceptive 
angiogenesis, occur in utero and in adults, with the latter 
one discovered just 20 years ago.33, 34 In contrast to 
sprouting angiogenesis characterized by sprouts of EC 
stimulated with VEGF-A, intussusceptive angiogenesis 
involves the formation of blood vessels by a splitting 
process in which elements of interstitial tissues invade 
existing vessels, forming transvascular tissue pillars that 
eventually expand. This type of angiogenesis is thought 
to be fast and efficient compared with sprouting 
angiogenesis because, initially, it only requires the 
reorganization of existing EC and does not rely on 
immediate endothelial proliferation or migration.35-37 
The control of intussusceptive angiogenesis is poorly 
understood compared with sprouting angiogenesis. 
Since capillary network already exists in BM, we can 
speculate that intussusceptive angiogenesis is the first 
process activated by changes in metabolic activity with 
oxygen as a pivotal player in this regulation since 
anemia is the leading MDS feature. The splitting of 
existent vessels can make new vessels with lower minor 
axis values, and with time blood vessels enlarge, and 
sprouting angiogenesis can take its part by accelerating 
angiogenesis resulting in higher MVD. 
In contrast, higher minor axis in CMML than MDS can 
be the result of an even more complex dynamic process 
in CMML that involves cell-cell and cell-extracellular 
matrix interactions directed spatially and temporally by 
growth factors and morphogens.38-41 This process 
includes the differentiation of mesodermal stem cells 
into fibroblasts activated by megakaryocytes producing 
fibrosis, changing the hemodynamic environment so 
small tortuous vessels and dilated sinusoids can be 
identified.41, 42 
We found no significant difference according to disease 
outcome, transfusion administration and progression of 
disease. However, MDS-IR patients received 
transfusions more frequently, while MDS-HR patients 
received chemotherapy significantly more frequently. 
The administration of transfusion in MDS-IR group 
confirms similar frequency like in the clinical trials.43-45 
Although the risk of progression and shorter overall 
survival is related to MDS-HR, in our study we found 
no difference related to it. Either more frequent 
intermediate and poor cytogenetic profiles in MDS-LR 
can influence shorter overall survival, or MDS-HR 
patients had longer survival and lower frequency of 
progression due to adequate chemotherapy.4 
More importance is attached to targeted therapy aimed 
at angiogenesis in hematologic malignancies. DNA 
methylation (DNMT) inhibitors 5-azacytidine and 5-
AZA-20-deoxycytidine were both approved for the 
treatment of higher-risk myelodysplastic syndromes. 
DNMT inhibitors appeared to have a role in 
angiogenesis inhibition, not only indirectly in the 
angiogenesis inhibition through the re-activation of 
tumor suppressor genes in cancer cells, but also having 
direct inhibitory effects through the epigenetic 
regulation in EC themselves.  Reversal of epigenetic 
modifications can be achieved by DNMT inhibitors 
mediated by the re-activation of angiogenesis-
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suppressing genes that have been silenced in tumor-
conditioned EC.46 Therefore, apart from the ‘standard’ 
modulators of angiogenesis, such as VEGF(R) or 
endothelial nitric oxide synthase, DNMT inhibitors may 
block or reverse the expression of certain EC genes and 
may be promising therapeutic targets. 
That can be supported by our results, taking into account 
that we found no difference in overall survival between 
MDS risk groups and MVD. Patients with minor and 
major axis median values of more than 50% had shorter 
overall survival (Figure 2, 3), indicating these are 
morphological features of prolonged angiogenesis 
which result in disease progression and drug resistance.  
In conclusion, enhanced MDS therapy presents an 
essential need for the majority of patients in all three 
MDS risk groups. Targeting tumor angiogenesis from 
early to advanced stages and relevant regulatory factors 
angiogenesis, inhibitors are mandatory to restrict tumor 
growth and metastasis as a new approach and effective 
oncotherapy. In recent years, combination therapy with 
multiple targets has provided a brand-new research 
direction for anti-angiogenesis. Although in this study 
disease progression within MDS is rather of qualitative 
than quantitative nature as regards tumor angiogenesis, 
a larger patient series is needed for clinical validation of 
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